FMC CEO sees slight decline in U.S. pay from 'rebasing'
FRANKFURT Feb 26 (Reuters) - Fresenius Medical Care expects only a slight reduction in U.S. reimbursement for services and drugs it provides to its dialysis patients from a ruling expected later this year.
When deliberating the payment policy of U.S. public-sector insurer Medicare in a process called rebasing, U.S. regulators would take into effect a decline in the amount of drugs needed for treatment but also the higher drug prices FMC has to pay to its suppliers, the group's Chief Executive Rice Powell told Reuters on Tuesday.
"We expect reimbursement to be slightly down," the CEO said.
He also said that automated "sequestration" budget cuts that will take effect in March - unless the White House and Congress agree on stopping them - would cost FMC $70 million this year.
- Obama and Castro shake hands, Zuma humiliated at Mandela memorial |
- Google bus blocked in San Francisco gentrification protest
- Reporter can keep sources secret in Colorado theater shooting: court
- Couple, four children missing in Nevada found safe in canyon
- Regulators seek to curb Wall St. trades with Volcker rule |